Evidence
Brain. 2024 Aug 31:awae278. doi: 10.1093/brain/awae278. Online ahead of print.
ABSTRACT
Complement activation is implicated in driving brain inflammation, self-cell damage and progression of injury in Alzheimer’s disease and other neurodegenerative diseases. Here, we investigate the impact of brain delivery of a complement-blocking antibody on neurodegeneration in an Alzheimer’s mouse model. We engineered a brain-penetrant recombinant antibody targeting the pro-inflammatory membrane attack complex. Systemic administration of this antibody in APPNL-G-F mice reduced brain levels of complement activation products, demonstrating successful brain entry and target engagement. Prolonged treatment decreased synapse loss, amyloid burden and brain inflammatory cytokine levels, concomitant with cognitive improvement compared to controls. These results underscore the potential of brain-penetrant complement-inhibiting drugs as promising therapeutics, targeting downstream of amyloid plaques in Alzheimer’s disease.
PMID:39215579 | DOI:10.1093/brain/awae278
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer’s disease mouse model
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Evidence Blueprint
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer’s disease mouse model
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer’s disease mouse model
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
